purified IgG. Azide was added before lyophilization.
Immunogen
Synthetic peptide (aa 1-16) of abeta peptides 38, 40, 42 coupled to key-hole limpet hemocyanin via an added C-terminal cysteine residue. Epitope aa 4-8
WB: 1 : 500 up to 1 : 1000 IP: not tested yet ICC: not tested yet IHC-P: 1 : 500 ELISA: not tested yet
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
For reconstitution add 100 µL H2O to get a 1mg/ml solution of antibody in PBS. Then aliquot and store at -20 °C until use.
Buffer
PBS, 0.02% sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Do not store diluted antibody solutions unless you add detergent or carrier proteins such as goat serum, BSA or others. IgG sticks to glass and plastic. Any IgG solution below 0.1 mg/mL protein will quickly adsorb and denature and thus loose activity! Repetitive freeze-thawing of dilute purified IgG is almost certain to lead to substantial losses.
Lagerung
-20 °C
Informationen zur Lagerung
Unlabeled antibodies are stable in this form without loss of quality at ambient temperatures for several weeks or even months. They can be stored at 4 °C for several years.
Porcellotti, Fanelli, Fracassi, Sepe, Cecconi, Bernardi, Cimini, Cerù, Moreno: "Oxidative Stress during the Progression of β-Amyloid Pathology in the Neocortex of the Tg2576 Mouse Model of Alzheimer's Disease." in: Oxidative medicine and cellular longevity, Vol. 2015, pp. 967203, (2015) (PubMed).
Reinert, Martens, Huettenrauch, Kolbow, Lannfelt, Ingelsson, Paetau, Verkkoniemi-Ahola, Bayer, Wirths: "Aβ38 in the brains of patients with sporadic and familial Alzheimer's disease and transgenic mouse models." in: Journal of Alzheimer's disease : JAD, Vol. 39, Issue 4, pp. 871-81, (2014) (PubMed).
Wirths, Hillmann, Pradier, Härtig, Bayer: "Oligomeric pyroglutamate amyloid-β is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy." in: Journal of Alzheimer's disease : JAD, Vol. 35, Issue 4, pp. 741-9, (2013) (PubMed).
Venkataramani, Wirths, Budka, Härtig, Kovacs, Bayer: "Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates." in: Journal of Alzheimer's disease : JAD, Vol. 29, Issue 2, pp. 361-71, (2012) (PubMed).